Could a diabetes drug and immune therapy slow Alzheimer's? new trial launches

NCT ID NCT07651319

Recruiting now Disease control Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether combining interleukin-2 (IL-2) with semaglutide (a diabetes drug) can safely reduce harmful inflammation in the brains of people with Alzheimer's disease. The study will enroll 30 adults aged 50–86 with mild-to-moderate Alzheimer's. Participants will receive either placebo, IL-2 alone, or IL-2 plus semaglutide for six months. Researchers will monitor safety, immune cell changes, and markers of brain health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Interleukin-2 (IL-2) and semaglutide
What this could lead to: If successful, this could point toward a new treatment that slows Alzheimer's progression by calming brain inflammation.
What could go wrong: This is an early, small trial (30 people) focused on safety. The combination may not show clear benefits, and side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DEMENTIA (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DEMENTIA (AD)

Contacts and locations

Locations

Houston Methodist Research Institute
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.